Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes

The panel gave its blessing to the lower 2mg dose of the JAK inhibitor for adult patients with moderately-to-severely active RA who don’t respond to or cannot tolerate ... But analysts think the drug faces an uphill battle now to win market share from

Latest news

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Lilly’s willingness to take a risk on continuing development of the drug in other indications may be cut now that it has won approval for JAK inhibitor Olumiant (baricitinib) for ... Meanwhile, Pharmacyclics (now part of AbbVie) has a BTK inhibitor

  • AbbVie reports more solid data for would-be psoriasis blockbuster AbbVie reports more solid data for would-be psoriasis blockbuster

    A pair of phase III trials pitting risankizumab against Johnson &Johnson’s older IL-12/IL-23 inhibitor Stelara (ustekinumab) - reported at the American Academy of Dermatology meeting in Chicago over ... Upadacitinib (also known as ABT-494) has been

  • J&J takes option on Theravance’s JAK drug in $1bn deal J&J takes option on Theravance’s JAK drug in $1bn deal

    TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients. Johnson &Johnson is paying $100m upfront for opt-in rights to a JAK inhibitor developed by Theravance, with another ... Seeking a piece of that opportunity, J&J is licensing

  • Celgene boosts haematology pipeline with $7bn Impact Bio deal Celgene boosts haematology pipeline with $7bn Impact Bio deal

    The US biotech is spending $1.1bn in upfront cash to buy Impact Bio and its late-stage drug candidate fedratinib, a JAK2 inhibitor in development for myelofibrosis and polycythaemia vera ... to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib

  • AbbVie’s JAK inhibitor upadacitinib clears another phase III trial AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

    AbbVie’ s JAK inhibitor upadacitinib clears another phase III trial. Moves a step closer to the rheumatoid arthritis market. ... AbbVie has moved a step closer to getting its JAK inhibitor upadacitinib onto the market for rheumatoid arthritis (RA)

More from news
Approximately 7 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during September 2013 Pharma deals during September 2013

    cancer, and AT13387, a second generation HSP90 inhibitor for the treatment of prostate and lung cancers. ... antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

  • Pharma deals during October 2012 Pharma deals during October 2012

    Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... 60. ‡‡ Ethical Oncology Science / Servier.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics